Updates are available Correction dated 2023-12-19
Click to view Correction: https://doi.org/10.1038/s41556-023-01336-0
-
Authors
Timms, Richard T. http://orcid.org/0000-0001-7275-597X
Mena, Elijah L.
Leng, Yumei
Li, Mamie Z.
Tchasovnikarova, Iva A.
Koren, Itay http://orcid.org/0000-0002-5693-1651
Elledge, Stephen J. http://orcid.org/0000-0001-7923-6283
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (n/a)
- License Information
-
More Information
Article History
Received: 10 December 2022
Accepted: 11 August 2023
First Online: 21 September 2023
Change Date: 19 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41556-023-01336-0
Competing interests
: S.J.E. is a founder of MAZE Therapeutics, Mirimus, TSCAN Therapeutics and ImmuneID, and serves on the scientific advisory board of Homology Medicines, TSCAN Therapeutics and MAZE Therapeutics; none of these associations impacts this work. All other authors declare no competing interests.
